# Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer

> **NCT04096911** · PHASE2 · UNKNOWN · sponsor: **Buhai Wang** · enrollment: 20 (estimated)

## Conditions studied

- Uterine Cervical Neoplasms
- Cervical Cancer
- Cervical Neoplasms
- Cervix Cancer

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** quadrivalent HPV vaccine

## Key facts

- **NCT ID:** NCT04096911
- **Lead sponsor:** Buhai Wang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-31
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-09-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04096911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04096911, "Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04096911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*